News

CLINUVEL
Posted by CLINUVEL
September 14, 2021

Presentation H.C. Wainwright Global Investment Conference

Melbourne, Australia, 14 September 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
September 2, 2021

CLINUVEL Kommuniqué IV

Sehr geehrte Aktionärinnen und Aktionäre, liebe Freunde, Einleitung Zufrieden blicken wir auf...

Read More
CLINUVEL
Posted by CLINUVEL
August 27, 2021

CLINUVEL Investor Webinar Financial Results Year Ended 30 June 2021

Melbourne, Australia, 27 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 26, 2021

CLINUVEL Communiqué IV

Dear Shareholders, Friends Introduction With satisfaction, we look back at an eventful...

Read More
CLINUVEL
Posted by CLINUVEL
August 26, 2021

Corporate Presentation - FY2021 Results

Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 26, 2021

Appendix 4E and Preliminary Financial Report

Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 26, 2021

CLINUVEL Delivers Record Revenues and Profit

Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 26, 2021

Dividend/Distribution - CUV

Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 10, 2021
CLINUVEL
Posted by CLINUVEL
August 10, 2021

Afamelanotide well tolerated by first stroke patients

CLINUVEL’s drug afamelanotide was well tolerated by the first three arterial ischaemic...

Read More
We use cookies to give you the best experience.